Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib plus local therapy in inoperable or surgery-refusing early-stage NSCLC
ChiCTR2600123356Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Two-year event-free survival rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600123356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123356.